🟢 Compass Pathways is trading 10.39% up today after positive 52-week COMP005 results showed second-dose benefit

Compass Pathways is trading 10.39% up at $15.50 after September 9, 2026, topline 52-week Phase 3 COMP005 results showed additional benefit from a second COMP360 dose.

• The 25 mg group reached an average 13-point MADRS reduction at Week 52, with 40%-45% response rates and approximately 30% remission rates; no new safety findings were reported.
• Shares also rose 5.80% on September 8, 2026, before accelerating despite broader U.S. market weakness, including declines in the S&P 500 and Nasdaq.